Literature DB >> 28576716

Enhanced targeting of invasive glioblastoma cells by peptide-functionalized gold nanorods in hydrogel-based 3D cultures.

Diana P N Gonçalves1, Raul D Rodriguez2, Thomas Kurth3, Laura J Bray4, Marcus Binner5, Christiane Jungnickel6, Fatih N Gür7, Steve W Poser8, Thorsten L Schmidt7, Dietrich R T Zahn2, Andreas Androutsellis-Theotokis8, Michael Schlierf9, Carsten Werner5.   

Abstract

Cancer stem cells (CSCs) are responsible for drug resistance, tumor recurrence, and metastasis in several cancer types, making their eradication a primary objective in cancer therapy. Glioblastoma Multiforme (GBM) tumors are usually composed of a highly infiltrating CSC subpopulation, which has Nestin as a putative marker. Since the majority of these infiltrating cells are able to elude conventional therapies, we have developed gold nanorods (AuNRs) functionalized with an engineered peptide capable of specific recognition and selective eradication of Nestin positive infiltrating GBM-CSCs. These AuNRs generate heat when irradiated by a near-infrared laser, and cause localized cell damage. Nanoparticle internalization assays performed with GBM-CSCs or Nestin negative cells cultured as two-dimensional (2D) monolayers or embedded in three-dimensional (3D) biodegradable-hydrogels of tunable mechanical properties, revealed that the AuNRs were mainly internalized by GBM-CSCs, and not by Nestin negative cells. The AuNRs were taken up via energy-dependent and caveolae-mediated endocytic mechanisms, and were localized inside endosomes. Photothermal treatments resulted in the selective elimination of GBM-CSCs through cell apoptosis, while Nestin negative cells remained viable. Results also indicated that GBM-CSCs embedded in hydrogels were more resistant to AuNR photothermal treatments than when cultured as 2D monolayers. In summary, the combination of our engineered AuNRs with our tunable hydrogel system has shown the potential to provide an in vitro platform for the evaluation and screening of AuNR-based cancer therapeutics, leading to a substantial advancement in the application of AuNRs for targeted GBM-CSC therapy. STATEMENT OF SIGNIFICANCE: There is an urgent need for reliable and efficient therapies for the treatment of Glioblastoma Multiforme (GBM), which is currently an untreatable brain tumor form with a very poor patient survival rate. GBM tumors are mostly comprised of cancer stem cells (CSCs), which are responsible for tumor reoccurrence and therapy resistance. We have developed gold nanorods functionalized with an engineered peptide capable of selective recognition and eradication of GBM-CSCs via heat generation by nanorods upon NIR irradiation. An in vitro evaluation of nanorod therapeutic activities was performed in 3D synthetic-biodegradable hydrogel models with distinct biomechanical cues, and compared to 2D cultures. Results indicated that cells cultured in 3D were more resistant to photothermolysis than in 2D systems.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D culture; Cancer stem cells; Glioblastoma Multiforme; Gold nanorods; Photothermolysis

Mesh:

Substances:

Year:  2017        PMID: 28576716     DOI: 10.1016/j.actbio.2017.05.054

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  10 in total

1.  Crosslinked Chitosan-PEG Hydrogel for Culture of Human Glioblastoma Cell Spheroids and Drug Screening.

Authors:  Fei-Chien Chang; Sheeny Lan Levengood; Nick Cho; Likai Chen; Everet Wang; John S Yu; Miqin Zhang
Journal:  Adv Ther (Weinh)       Date:  2018-08-13

2.  Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.

Authors:  Wei Jia; Xingjun Jiang; Weidong Liu; Lei Wang; Bin Zhu; Hecheng Zhu; Xingdong Liu; Meizuo Zhong; Dan Xie; Wei Huang; Wenting Jia; Shasha Li; Xuxu Liu; Xiang Zuo; Damei Cheng; Jianwu Dai; Caiping Ren
Journal:  Int J Oncol       Date:  2018-03-20       Impact factor: 5.650

3.  Gold Nanopeanuts as Prospective Support for Cisplatin in Glioblastoma Nano-Chemo-Radiotherapy.

Authors:  Joanna Depciuch; Justyna Miszczyk; Alexey Maximenko; Piotr M Zielinski; Kamila Rawojć; Agnieszka Panek; Pawel Olko; Magdalena Parlinska-Wojtan
Journal:  Int J Mol Sci       Date:  2020-11-29       Impact factor: 5.923

4.  Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma.

Authors:  Nicole F Bonan; Debbie K Ledezma; Matthew A Tovar; Preethi B Balakrishnan; Rohan Fernandes
Journal:  Nanomaterials (Basel)       Date:  2022-08-01       Impact factor: 5.719

Review 5.  Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.

Authors:  Amir Barzegar Behrooz; Zahra Talaie; Amir Syahir
Journal:  Pharmaceutics       Date:  2022-08-15       Impact factor: 6.525

6.  Techniques for RNA extraction from cells cultured in starPEG-heparin hydrogels.

Authors:  Anna Jaeschke; Nicholas R Harvey; Mikhail Tsurkan; Carsten Werner; Lyn R Griffiths; Larisa M Haupt; Laura J Bray
Journal:  Open Biol       Date:  2021-06-02       Impact factor: 6.411

Review 7.  The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.

Authors:  Xiaotong Li; Minghong Jian; Yanhong Sun; Qunyan Zhu; Zhenxin Wang
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

Review 8.  Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?

Authors:  Claire Gazaille; Marion Sicot; Patrick Saulnier; Joël Eyer; Guillaume Bastiat
Journal:  Front Med Technol       Date:  2021-11-22

9.  Well-Defined Polyethylene Glycol Microscale Hydrogel Blocks Containing Gold Nanorods for Dual Photothermal and Chemotherapeutic Therapy.

Authors:  Ben Newland; Johannes Starke; Chiara Bastiancich; Diana P N Gonçalves; Laura J Bray; Wenxin Wang; Carsten Werner
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

Review 10.  Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements.

Authors:  Atieh Jahangiri-Manesh; Marziyeh Mousazadeh; Shirinsadat Taji; Abbas Bahmani; Atefeh Zarepour; Ali Zarrabi; Esmaeel Sharifi; Mostafa Azimzadeh
Journal:  Pharmaceutics       Date:  2022-03-17       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.